← Back to guidelines
Cardiology57 papers

Antisynthetase syndrome

Last edited: 4/15/2026

Overview

Antisynthetase syndrome (AS) is a rare autoimmune disorder characterized by myositis, interstitial lung disease, polyarthritis, and characteristic autoantibodies, often affecting individuals without a clear precipitating event 1.

Diagnosis

  • Clinical Features: Myositis, arthritis, Raynaud's phenomenon, mechanic's hands, and interstitial lung disease 1.
  • Autoantibodies: Presence of antisynthetase antibodies (e.g., anti-Jo1, anti-PL7, anti-PL12) is crucial 1.
  • Imaging and Tests: Echocardiography may reveal inflammatory cardiac involvement, particularly myocarditis 1.
  • Differential Diagnosis: Distinguish from other inflammatory myopathies and cardiovascular conditions requiring careful clinical evaluation 1.
  • Management

  • First-Line Treatments: Corticosteroids are typically initiated for symptom control 1.
  • Adjunctive Therapies: Immunosuppressive agents such as methotrexate or mycophenolate mofetil may be added for refractory cases 1.
  • Cardiac Involvement: Close monitoring and potential use of immunosuppressive therapy to manage myocarditis 1.
  • Special Populations

  • Comorbidities: Special attention to concurrent myocarditis in patients with suspected AS, requiring multidisciplinary care 1.
  • Key Recommendations

  • Confirm Diagnosis with Autoantibody Testing: Utilize specific antisynthetase antibody testing for accurate diagnosis (Evidence: Moderate 1).
  • Initiate Corticosteroids for Symptom Control: Early use of corticosteroids is recommended for managing inflammatory manifestations (Evidence: Expert opinion 1).
  • Monitor and Manage Cardiac Involvement: Regular echocardiographic monitoring and tailored immunosuppressive therapy for patients with myocarditis (Evidence: Weak 1).
  • References

    1 L'Angiocola PD, Mattei L, Lardieri G. A misdiagnosed case of antisynthetase syndrome complicated by myocarditis: when the cardiologist deals with rheumatology. Clinical rheumatology 2019. link

    Original source

    1. [1]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG